Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-16), Formycon AG's 9-Day RSI is 34.78.
The industry rank for Formycon AG's 9-Day RSI or its related term are showing as below:
WBO:FYB's 9-Day RSI is ranked better than 82.14% of 1422
companies
in the Biotechnology industry
Industry Median: 48.66
vs WBO:FYB: 34.78
Formycon AG (WBO:FYB) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Formycon AG 9-Day RSI Related Terms
WBO:FYB vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Formycon AG's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Formycon AG's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formycon AG (WBO:FYB) has a 9-Day RSI of 34.78 as of Jul. 16, 2026. According to the industry distribution chart, Formycon AG ranks #254 out of 1422 companies in the Biotechnology industry, placing it in the top 17.9%.
Is Formycon AG's 9-Day RSI too high?
Formycon AG's current 9-Day RSI is 34.78. The Biotechnology industry median 9-Day RSI is 48.66. Formycon AG's value of 34.78 is 28.5% below this industry median. Based on the distribution chart, Formycon AG ranks #254 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Formycon AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #254 out of 1422 companies for 9-Day RSI. This places Formycon AG in the top 18% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 48.66. Formycon AG's value of 34.78 is 28.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 48.66, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formycon AG's current 9-Day RSI of 34.78 is 28.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 48.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formycon AG's current 9-Day RSI is 34.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (WBO:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €37.37, compared to a current price of €18.30 — trading 51% below its estimated fair value. The current 9-Day RSI is 34.78 and 28.5% below the Biotechnology industry median of 48.66. Formycon AG's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Formycon AG (WBO:FYB), the current 9-Day RSI is 34.78 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (WBO:FYB) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €18.30 is trading 51% below its estimated GF Value™ of €37.37.
GuruFocus considers Formycon AG to be Possible Value Trap.
Key valuation signals for WBO:FYB:
9-Day RSI: 34.78
GF Value™: €37.37 vs. price of €18.30 (51% below fair value)
Industry Position: 28.5% below the Biotechnology median (#254 of 1422)
No single metric tells the full story. See the WBO:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
39GF Score
Get the complete analysis for WBO:FYB
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:FYB has been successfully added to your 
